178 related articles for article (PubMed ID: 16432547)
1. Weight loss in overweight patients maintained on atypical antipsychotic agents.
Centorrino F; Wurtman JJ; Duca KA; Fellman VH; Fogarty KV; Berry JM; Guay DM; Romeling M; Kidwell J; Cincotta SL; Baldessarini RJ
Int J Obes (Lond); 2006 Jun; 30(6):1011-6. PubMed ID: 16432547
[TBL] [Abstract][Full Text] [Related]
2. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
Chen CK; Chen YC; Huang YS
Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
[TBL] [Abstract][Full Text] [Related]
3. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
[TBL] [Abstract][Full Text] [Related]
4. Effects of an educational intervention on weight gain in patients treated with antipsychotics.
Mauri M; Castrogiovanni S; Simoncini M; Iovieno N; Miniati M; Rossi A; Dell'Agnello G; Fagiolini A; Donda P; Cassano GB
J Clin Psychopharmacol; 2006 Oct; 26(5):462-6. PubMed ID: 16974185
[TBL] [Abstract][Full Text] [Related]
5. A seven-year follow-up of a weight reduction programme in Finnish primary health care.
Karvetti RL; Hakala P
Eur J Clin Nutr; 1992 Oct; 46(10):743-52. PubMed ID: 1425528
[TBL] [Abstract][Full Text] [Related]
6. Medication associated with weight gain may influence outcome in a weight management program.
Malone M; Alger-Mayer SA; Anderson DA
Ann Pharmacother; 2005; 39(7-8):1204-8. PubMed ID: 15928261
[TBL] [Abstract][Full Text] [Related]
7. Weight gain and antipsychotic medication.
Blackburn GL
J Clin Psychiatry; 2000; 61 Suppl 8():36-41; discussion 42. PubMed ID: 10811242
[TBL] [Abstract][Full Text] [Related]
8. Effect of a moderately hypoenergetic Mediterranean diet and exercise program on body cell mass and cardiovascular risk factors in obese women.
Andreoli A; Lauro S; Di Daniele N; Sorge R; Celi M; Volpe SL
Eur J Clin Nutr; 2008 Jul; 62(7):892-7. PubMed ID: 17522604
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics].
Cordes J; Sinha-Röder A; Kahl KG; Malevani J; Thuenker J; Lange-Asschenfeldt C; Hauner H; Agelink MW; Klimke A
Fortschr Neurol Psychiatr; 2008 Dec; 76(12):703-14. PubMed ID: 18924059
[TBL] [Abstract][Full Text] [Related]
10. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
[TBL] [Abstract][Full Text] [Related]
11. A program for managing weight gain associated with atypical antipsychotics.
Vreeland B; Minsky S; Menza M; Rigassio Radler D; Roemheld-Hamm B; Stern R
Psychiatr Serv; 2003 Aug; 54(8):1155-7. PubMed ID: 12883145
[TBL] [Abstract][Full Text] [Related]
12. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
13. Effects of second generation antipsychotics on leptin and ghrelin.
Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
[TBL] [Abstract][Full Text] [Related]
14. [Schizophrenia, obesity and pharmacotherapy-associated weight gain].
Carpiniello B; Corda E; Maccioni R; Pinna F
Clin Ter; 2008; 159(5):299-306. PubMed ID: 18998030
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic-associated weight gain and clinical outcome parameters.
Blin O; Micallef J
J Clin Psychiatry; 2001; 62 Suppl 7():11-21. PubMed ID: 11346191
[TBL] [Abstract][Full Text] [Related]
16. Weight loss induced by nutritional and exercise intervention decreases arterial stiffness in obese subjects.
Goldberg Y; Boaz M; Matas Z; Goldberg I; Shargorodsky M
Clin Nutr; 2009 Feb; 28(1):21-5. PubMed ID: 19019502
[TBL] [Abstract][Full Text] [Related]
17. Effects of obesity reduction on cardiovascular risk factors: comparison of individual and group treatment--substudy of the Croatian Healthy Weight Loss Programme.
Jovanović Z; Crncević-Orlić Z; Stimac D; Kokić S; Persić V; Ruzić T; Goll-Barić S
Coll Antropol; 2009 Sep; 33(3):751-7. PubMed ID: 19860100
[TBL] [Abstract][Full Text] [Related]
18. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.
Kim E; Park DW; Choi SH; Kim JJ; Cho HS
J Clin Psychopharmacol; 2008 Apr; 28(2):138-46. PubMed ID: 18344723
[TBL] [Abstract][Full Text] [Related]
19. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program.
Menza M; Vreeland B; Minsky S; Gara M; Radler DR; Sakowitz M
J Clin Psychiatry; 2004 Apr; 65(4):471-7. PubMed ID: 15119908
[TBL] [Abstract][Full Text] [Related]
20. A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease.
Cook SA; MacLaughlin H; Macdougall IC
Nephrol Dial Transplant; 2008 Jan; 23(1):263-8. PubMed ID: 17977872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
